NCT07913347 Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 54 participants in total. It began in 2026-07-09 with a primary completion date of 2028-03-31.

Brief Summary

Ulcerative colitis is a condition that causes inflammation and ulcers in the large intestine. MGT-006 is an investigational oral capsule containing viable gut microbiota from screened human donors. This study will evaluate the safety and tolerability of MGT-006 in adults with moderately active ulcerative colitis. It will also examine whether gut microbiota from MGT-006 engraft in participants' intestines and explore changes in ulcerative colitis symptoms and inflammation. The study has two parts. In Phase 1b, participants will be randomly assigned to receive MGT-006 either without antibiotic pretreatment or after five days of oral vancomycin or AFM (Amoxicillin/Fosfomycin/Metronidazole) pretreatment. MGT-006 will be taken for eight weeks, followed by four weeks of observation. Phase 2a is planned to explore different doses and potentially different dosing regimens of MGT-006, using the pretreatment approach selected from Phase 1b. The final Phase 2a design will depend on the Phase 1b findings and will be specified in an amended protocol before Phase 2a begins.

Eligibility Criteria

Inclusion Criteria: 1. Patients who understand the contents of this clinical study, sign a written informed consent form, and possess the willingness and capability to participate in all medical examinations, evaluations, and follow-ups related to the study. 2. Patients aged 18 to 75 years at the time of informed consent 3. Patients who have been diagnosed with UC through endoscopic and histological examination for at least 12 weeks at the time of final registration 4. Patients with a modified Mayo Score of 4 to 7 at the time of final registration Exclusion Criteria: 1. Patients with any of the following medical history or complications, or those undergoing concomitant therapy, which the investigator (sub-investigator) to be serious or clinically significant 2. Patients with past or concurrent malignant tumors; however, cured basal cell carcinoma of the skin is allowed for registration. In addition, breast cancer in remission for \>= 10 years without recurrence is allowed for registration, and other malignant tumors in remission for \>= 5 years are allowed for registration if no therapeutic intervention is required and they are in stable condition, as determined by the investigator (sub-investigator). 3. Patients with pancolitis of \> 8 years' duration or left-sided colitis of \> 8 years' duration who have not undergone a surveillance flexible sigmoidoscopy or total colonoscopy (performed according to local standard of care) within 12 months prior to screening to rule out colorectal dysplasia/cancer. 4. Patients with suspected or confirmed colorectal cancer or high-grade dysplasia. 5. Patients with any of the following abnormal values in clinical laboratory tests performed within 4 weeks prior to final registration in this clinical study: * Patients with a serum creatinine level of \>= 2.0 mg/dL or a BUN level of \>= 25 mg/dL * Patients with a total bilirubin level of \>= 3.0 mg/dL, or an AST (GOT) or ALT (GPT) level of \>= 100 IU/L 6. Patients with any of the following will be excluded: * HBsAg positive * HCV antibody positive * HIV-1/2 Ag/Ab screening-positive 7. Patients currently receiving inpatient treatment for UC 8. Patients suspected to have concurrent active intestinal obstruction or infectious enteritis 9. Patients with Clostridioides difficile infection (C. difficile infection) (patients in whom the presence or absence of infection is confirmed by NAAT and the result is positive) 10. Patients with a history of hypersensitivity or allergy to excipients in MGT-006 11. Patients with any of the following conditions that affect the lower gastrointestinal function 12. Patients who have failed or been intolerant to \>= 3 advanced-therapy mechanistic classes for ulcerative colitis (e.g., anti-TNF, anti-integrin, anti-IL-12/23, JAK inhibitor, S1P modulator) 13. Patients who have used another investigational product within 12 weeks prior to informed consent 14. Patients with serious allergies or contraindications to any drug used in this study 15. (Females only) Patients in whom the result of a pregnancy test performed within 4 weeks prior to final registration is positive (if a urine hCG test is positive, a negative serum pregnancy test result should be confirmed) 16. (Females only) Patients who are pregnant or breastfeeding, or females of childbearing potential unable to use appropriate contraceptive methods from the date of informed consent to 12 weeks post-treatment. (e.g., intrauterine device, diaphragm, partner's use of condom) 17. (Males only) Patients who are males of reproductive potential (including partners of childbearing potential) unable to use at least one effective contraceptive method from the time of informed consent until 12 weeks after the end of investigational drug administration 18. Patients judged by the investigator (sub-investigator) to be inappropriate as subjects of this study 19. (Phase 2a only) Participants who have previously received MGT-006

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.